Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Analysts at William Blair reduced their Q3 2017 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.95) per share for the quarter, down from their prior forecast of ($0.94). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Atara Biotherapeutics’ Q4 2017 earnings at ($0.98) EPS, FY2017 earnings at ($3.75) EPS, Q1 2018 earnings at ($1.00) EPS, Q2 2018 earnings at ($1.00) EPS, Q3 2018 earnings at ($1.02) EPS, Q4 2018 earnings at ($0.91) EPS, FY2018 earnings at ($3.94) EPS, FY2019 earnings at ($3.23) EPS, FY2020 earnings at ($2.51) EPS and FY2021 earnings at ($2.10) EPS.

Several other research analysts also recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a research note on Friday, April 21st. Jefferies Group LLC restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Finally, ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $25.75.

COPYRIGHT VIOLATION NOTICE: “William Blair Weighs in on Atara Biotherapeutics, Inc.’s Q3 2017 Earnings (ATRA)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/william-blair-weighs-in-on-atara-biotherapeutics-inc-s-q3-2017-earnings-atra/1467167.html.

Shares of Atara Biotherapeutics (NASDAQ ATRA) opened at 14.50 on Thursday. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.40. The stock has a 50 day moving average of $15.02 and a 200-day moving average of $15.89. The firm’s market capitalization is $422.08 million.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05.

In related news, CFO John Mcgrath sold 4,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $15.11, for a total value of $60,440.00. Following the sale, the chief financial officer now directly owns 113,762 shares of the company’s stock, valued at $1,718,943.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gad Soffer sold 12,674 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $15.16, for a total transaction of $192,137.84. Following the completion of the sale, the executive vice president now directly owns 259,527 shares in the company, valued at $3,934,429.32. The disclosure for this sale can be found here. Insiders sold 54,308 shares of company stock worth $797,382 over the last ninety days. 16.10% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Redmile Group LLC boosted its stake in Atara Biotherapeutics by 2.4% in the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock valued at $56,186,000 after buying an additional 63,176 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Atara Biotherapeutics during the first quarter valued at about $132,000. Vident Investment Advisory LLC boosted its stake in Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock valued at $1,144,000 after buying an additional 9,276 shares in the last quarter. EcoR1 Capital LLC boosted its stake in Atara Biotherapeutics by 101.5% in the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock valued at $8,935,000 after buying an additional 219,000 shares in the last quarter. Finally, State Street Corp boosted its stake in Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares in the last quarter. 81.50% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.